Cilostazol/ginkgo-biloba

Drug Profile

Cilostazol/ginkgo-biloba

Alternative Names: Cilostazol/ginkgo-biloba controlled release; Cilostazol/ginkgo-biloba immediate release; Renexin; SID 142

Latest Information Update: 26 Feb 2016

Price : $50

At a glance

  • Originator SK Chemicals
  • Developer Asan Medical Center; SK Chemicals
  • Class Antiplatelets; Herbal medicines; Neuroprotectants; Small molecules; Tetrazoles
  • Mechanism of Action Platelet aggregation inhibitors; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Myocardial infarction
  • Phase III Ear disorders
  • Phase I Arterial occlusive disorders

Most Recent Events

  • 14 Feb 2016 SK Chemicals terminates phase III trial in Recurrent Vestibulopathy in South Korea (PO, Immediate release) (NCT01895400)
  • 01 Jul 2015 SK Chemicals completes a phase I trial in Arterial occlusive disorders in South Korea (PO, Controlled release) (NCT02625714)
  • 01 Jun 2015 Phase-I clinical trials in Arterial occlusive disorders in South Korea (PO, Controlled release) (NCT02625714)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top